FOLH1 and prostate cancer: In patients with oligorecurrent prostate cancer after radical prostatectomy, prostate-specific membrane antigen–targeted radioguided surgery (PSMA-RGS) may prolong treatment-free survival without negatively affecting the quality of life or any functional status domains, except sexual.